<DOC>
	<DOCNO>NCT00870740</DOCNO>
	<brief_summary>The primary objective study assess safety immunogenicity extend treatment DAC HYP . This evaluation include follow major component : - An assessment safety immunogenicity extend treatment DAC HYP administer MS subject complete 52 week active therapy DAC HYP Study 201 . - An assessment safety immunogenicity 6-month washout period DAC HYP . - An assessment safety immunogenicity reinitiation therapy DAC HYP 6-month washout period . - An assessment safety immunogenicity DAC HYP administer MS subject previously receive placebo Study 201 . The secondary objective ass durability effect DAC HYP multiple sclerosis ( MS ) disease activity measure brain magnetic resonance imaging ( MRI ) scan clinical MS relapse .</brief_summary>
	<brief_title>Safety Efficacy Extension Study Daclizumab High Yield Process ( DAC HYP ) Participants With Multiple Sclerosis Who Have Completed Study 205MS201 ( NCT00390221 ) Treat Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description>This study , extension Study 205MS201 ( NCT00390221 ) , evaluate long-term safety , efficacy , immunogenicity DAC HYP MS . In Study 205MS201 , study treatment schedule stop Week 52 visit . This extension study provide initiation active therapy DAC HYP among participant receive placebo Weeks 0 52 205MS201 . In addition , participant receive active therapy DAC HYP Weeks 0 52 Study 205MS201 continue DAC HYP therapy resume DAC HYP therapy 6-month washout period study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Key Participated Study 205MS201 ( NCT00390221 ) least 52 week compliant 205MS201 protocol opinion Investigator . Key Subjects significant change medical status 205MS201 would preclude administration DAC HYP , determine Investigator Any subject permanently discontinue study treatment Study 205MS201 except subject unblinded evaluation adverse event ( AE ) find placebo Planned ongoing treatment approve experimental treatment MS except protocolallowed use concomitant interferonbeta NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>MS</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>